BioMarin Pharmaceutical

Categories

Pharma and Life Sciences  

#1077

Rank

$16B

MarketCap US

US United States

Country

Summary

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. 

Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.


History

1997: BioMarin (BMRN) is based in San Rafael, California, and was founded. When BioMarin first opened its doors+, treatment of rare diseases was as rare as the conditions themselves.

1999: BioMarin was listed on the NASDAQ stock exchange.

2009: BioMarin acquired Huxley Pharmaceuticals Inc.


Mission

To bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide.


Vision

At BioMarin, we view ourselves as a team of pioneers willing to take risks in the quest to find new solutions to address the biggest challenges in rare diseases, and motivated by the desire to help improve the lives of patients with unmet medical needs.


Key Team

Alan Lewis (Board Member)

Alan Lewis (Board Member)

David E.I. Pyott, M.D. (Hon.) (Board Member)

Aman Bains (CMO Sr. Associate)

Elaine J. Heron (Board Member)

Andrea L. Acosta (Group Vice President and Chief Accounting Officer)

Elizabeth McKee Anderson (Board Member)

Becky Stamps (Sr. Executive Coordinator To Chief Scientific Strategy Officer)

Kenneth Bate (Board Member)

Brian R. Mueller (Executive Vice President and Chief Financial Officer)

Mike Grey (Board Member)

Charles Greg Guyer (Chief Technical Officer and Executive Vice President)

Randy Meier (Board Member)

Cybelle Mandigo (External Manufacturing (CMO) Manager)

Richard A. Meier (Board Member)

Christopher Starr (Founder)

Robert A Baffi (Special Advisor To The Chairman & Chief Executive Officer)

Grant Denison Jr. (Founder)

Jean Jacques Bienaime (CEO)


Recognition and Awards
Forbes: Most Innovative Companies

References
BioMarin Pharmaceutical
Leadership team

Christopher Starr (Founder)

Grant Denison Jr. (Founder)

Industries

Pharma and Life Sciences

Products/ Services
Kuvan, Naglazyme, Aldurazyme, Firdapse, Vimizim, Brineura, Palynziq
Number of Employees
1,000 - 20,000
Headquarters
San Rafael, California, United States
Established
1997
Company Type
Public Limited Company
Company Registration
SEC CIK number: 0001048477
Net Income
20M - 100M
Revenue
Above - 1B
Traded as
BMRN
Social Media

Related Companies

Related Companies

Fri Mar 01 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium